Market Research Logo

Dry (Atrophic) Macular Degeneration - Pipeline Review, H2 2016

Dry (Atrophic) Macular Degeneration - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dry (Atrophic) Macular Degeneration – Pipeline Review, H2 2016, provides an overview of the Dry (Atrophic) Macular Degeneration (Ophthalmology) pipeline landscape.

Dry atrophic macular degeneration is generally characterized by a slow but progressive visual loss. This is characterized by yellow spots under the retina, called drusen, which are accumulations of metabolic waste products. Symptoms include blurred or decreased central close-up and distance vision, blind spots, micropsia and straight lines look distorted. Predisposing factors include age and family history.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dry (Atrophic) Macular Degeneration – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Dry (Atrophic) Macular Degeneration (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dry (Atrophic) Macular Degeneration (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Dry (Atrophic) Macular Degeneration and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 10, 2, 14, 7 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.Dry (Atrophic) Macular Degeneration.

Dry (Atrophic) Macular Degeneration (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:

Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Dry (Atrophic) Macular Degeneration (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Dry (Atrophic) Macular Degeneration (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Dry (Atrophic) Macular Degeneration (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Dry (Atrophic) Macular Degeneration (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Dry (Atrophic) Macular Degeneration (Ophthalmology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Dry (Atrophic) Macular Degeneration (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Dry (Atrophic) Macular Degeneration (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Dry (Atrophic) Macular Degeneration Overview
Therapeutics Development
Pipeline Products for Dry (Atrophic) Macular Degeneration - Overview
Pipeline Products for Dry (Atrophic) Macular Degeneration - Comparative Analysis
Dry (Atrophic) Macular Degeneration - Therapeutics under Development by Companies
Dry (Atrophic) Macular Degeneration - Therapeutics under Investigation by Universities/Institutes
Dry (Atrophic) Macular Degeneration - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Dry (Atrophic) Macular Degeneration - Products under Development by Companies
Dry (Atrophic) Macular Degeneration - Products under Investigation by Universities/Institutes
Dry (Atrophic) Macular Degeneration - Companies Involved in Therapeutics Development
Aciont Inc.
Alimera Sciences, Inc.
Allergan Plc
Apellis Pharmaceuticals Inc
Astellas Pharma Inc.
Benitec Biopharma Limited
Biophytis SAS
Catalyst Biosciences, Inc.
Cell Cure Neurosciences, Ltd.
Charlesson LLC.
Foamix Pharmaceuticals Ltd.
Genentech Inc
GenSight Biologics S.A.
GlaxoSmithKline Plc
Icon Bioscience, Inc.
Inception Sciences, Inc.
Johnson & Johnson
Kodiak Sciences Inc.
MacuCLEAR Inc
MeiraGTx Limited
Novartis AG
Ophthotech Corp.
Orphagen Pharmaceuticals, Inc.
pSivida Corp.
Samumed LLC
Sucampo Pharmaceuticals, Inc.
Sun Pharma Advanced Research Co Ltd
Dry (Atrophic) Macular Degeneration - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
A-005 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APL-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
avacincaptad pegol sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BBAMD-231 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BIO-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
brimonidine tartrate implant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CLG-561 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CLT-005 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CNTO-2476 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug for Age Related Macular Degeneration - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EG-30 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FMX-103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Dry Macular Degeneration and Retinitis Pigmentosa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Ocular Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GS-030 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-933776 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ICR-14967 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KSI-401 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lampalizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MA09-hRPE - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MC-1101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
methotrexate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OCU-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ONL-1204 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OpRegen - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OpRegen Plus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RC-1 Alpha - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Enzymes to Inhibit Complement C3 for Dry Age-Related Macular Degeneration - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RST-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Dry AMD and Wet AMD - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for AMD - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Dry Age-Related Macular Degeneration - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Dry AMD - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Dry and Wet Age Related Macular Degeneration - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit NADPH Oxidase for Dry Macular Degeneration - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Activate CD36 Receptor for Cardiovascular Diseases and Macular Degeneration - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tesidolumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
unoprostone isopropyl - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VM-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Dry (Atrophic) Macular Degeneration - Dormant Projects
Dry (Atrophic) Macular Degeneration - Discontinued Products
Dry (Atrophic) Macular Degeneration - Product Development Milestones
Featured News & Press Releases
Aug 30, 2016: RetroSense Therapeutics Granted Patent on Proprietary Method for Restoring Vision using Optogenetics
May 05, 2016: RetroSense Therapeutics to Highlight Contributions to Gene Therapy Research in Upcoming Conferences
Apr 12, 2016: BIOPHYTIS to Present Pre-Clinical Data on BIO 201 at Upcoming Scientific Conference
Nov 17, 2015: Biophytis establishes New subsidiary to accelerate clinical development of Maculia
Oct 01, 2013: Roche to present data on Lampalizumab at investor event
Aug 27, 2013: Roche’s lampalizumab phase II data shows benefit in patients with the advanced form of dry age-related macular degeneration
Jul 17, 2013: ACT Secures Approval from Data Safety Monitoring Board to Complete Third Patient Cohort in All Three Clinical Trials
May 16, 2013: ACT Confirms Clinical Trial Participant Shows Improvement In Vision Following Treatment With Human Embryonic Stem Cells
Apr 15, 2013: ACT Treats First Patient with Better Vision in Clinical Trial for Stargardt’s Macular Dystrophy
Apr 01, 2013: ACT Initiates Treatment Of Higher-dosage Cohort In Clinical Trials For Dry Age-related Macular Degeneration And Stargardt's Macular Dystrophy
Mar 14, 2013: Advanced Cell Technology Receives DSMB Approval To Initiate Treatment Of Third Patient Cohort In All Three Clinical Trials Using hESC-derived RPE Cells
Feb 15, 2013: OgenX Therapeutics Announces Presentation Of RAVEN-1 Trial Final Results At Snowmass Ophthalmology Conference
Jan 08, 2013: Advanced Cell Technology Achieves Clinical Milestone
Nov 28, 2012: ACT Completes Higher-Dosage Cohort In Both US Clinical Trials Using Retinal Pigment Epithelial Cells
Aug 02, 2012: ACT Announces First Dry Age-Related Macular Degeneration Patient Treated With Higher Dosage Of Embryonic Stem Cell-Derived RPE Cells
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Dry (Atrophic) Macular Degeneration, H2 2016
Number of Products under Development for Dry (Atrophic) Macular Degeneration - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2016
Dry (Atrophic) Macular Degeneration - Pipeline by Aciont Inc., H2 2016
Dry (Atrophic) Macular Degeneration - Pipeline by Alimera Sciences, Inc., H2 2016
Dry (Atrophic) Macular Degeneration - Pipeline by Allergan Plc, H2 2016
Dry (Atrophic) Macular Degeneration - Pipeline by Apellis Pharmaceuticals Inc, H2 2016
Dry (Atrophic) Macular Degeneration - Pipeline by Astellas Pharma Inc., H2 2016
Dry (Atrophic) Macular Degeneration - Pipeline by Benitec Biopharma Limited, H2 2016
Dry (Atrophic) Macular Degeneration - Pipeline by Biophytis SAS, H2 2016
Dry (Atrophic) Macular Degeneration - Pipeline by Catalyst Biosciences, Inc., H2 2016
Dry (Atrophic) Macular Degeneration - Pipeline by Cell Cure Neurosciences, Ltd., H2 2016
Dry (Atrophic) Macular Degeneration - Pipeline by Charlesson LLC., H2 2016
Dry (Atrophic) Macular Degeneration - Pipeline by Foamix Pharmaceuticals Ltd., H2 2016
Dry (Atrophic) Macular Degeneration - Pipeline by Genentech Inc, H2 2016
Dry (Atrophic) Macular Degeneration - Pipeline by GenSight Biologics S.A., H2 2016
Dry (Atrophic) Macular Degeneration - Pipeline by GlaxoSmithKline Plc, H2 2016
Dry (Atrophic) Macular Degeneration - Pipeline by Icon Bioscience, Inc., H2 2016
Dry (Atrophic) Macular Degeneration - Pipeline by Inception Sciences, Inc., H2 2016
Dry (Atrophic) Macular Degeneration - Pipeline by Johnson & Johnson, H2 2016
Dry (Atrophic) Macular Degeneration - Pipeline by Kodiak Sciences Inc., H2 2016
Dry (Atrophic) Macular Degeneration - Pipeline by MacuCLEAR Inc, H2 2016
Dry (Atrophic) Macular Degeneration - Pipeline by MeiraGTx Limited, H2 2016
Dry (Atrophic) Macular Degeneration - Pipeline by Novartis AG, H2 2016
Dry (Atrophic) Macular Degeneration - Pipeline by Ophthotech Corp., H2 2016
Dry (Atrophic) Macular Degeneration - Pipeline by Orphagen Pharmaceuticals, Inc., H2 2016
Dry (Atrophic) Macular Degeneration - Pipeline by pSivida Corp., H2 2016
Dry (Atrophic) Macular Degeneration - Pipeline by Samumed LLC, H2 2016
Dry (Atrophic) Macular Degeneration - Pipeline by Sucampo Pharmaceuticals, Inc., H2 2016
Dry (Atrophic) Macular Degeneration - Pipeline by Sun Pharma Advanced Research Co Ltd, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Dry (Atrophic) Macular Degeneration - Dormant Projects, H2 2016
Dry (Atrophic) Macular Degeneration - Dormant Projects (Contd..1), H2 2016
Dry (Atrophic) Macular Degeneration - Dormant Projects (Contd..2), H2 2016
Dry (Atrophic) Macular Degeneration - Discontinued Products, H2 2016
List of Figures
Number of Products under Development for Dry (Atrophic) Macular Degeneration, H2 2016
Number of Products under Development for Dry (Atrophic) Macular Degeneration - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report